Browse the evidence

Evidence that behavioral weight management programs reduce the incidence of cardiovascular disease or type 2 diabetes is currently sparse and uncertain.

While BWMPs improve risk factors, do not expect them to definitively prevent heart disease or diabetes based on current evidence. The data is too sparse to draw firm conclusions about disease incidence reduction.

Semaglutide improves insulin sensitivity and glucose uptake in skeletal muscle and adipose tissue by activating the PI3K/AKT and AMPK/SIRT1 pathways, leading to GLUT4 translocation, independent of direct insulin action in some contexts.

Semaglutide helps your body use insulin better by activating specific cellular pathways (AMPK/SIRT1) that move glucose into muscles and fat cells. This reduces insulin resistance, a key factor in type 2 diabetes and obesity.

Coffee consumption (caffeinated and decaffeinated) is inversely associated with liver fibrosis, abnormal liver function tests, and hepatocellular carcinoma risk in NAFLD patients.

If you tolerate it, drinking coffee (caffeinated or decaf) may help protect your liver from scarring and cancer. It is a simple, low-cost addition to a liver-healthy lifestyle.

HMB supplementation provides minor, inconsistent support for increasing or retaining lean soft-tissue mass (LSTM) in older or clinical populations, but has no evidence of improving physical function.

If you are older or clinically frail, HMB might offer a small benefit for retaining lean mass, especially if you are not exercising. However, do not expect it to improve your strength or physical function. It is not a substitute for exercise or adequate protein intake. If you are healthy and exercising, HMB likely adds no value.

Liraglutide attenuates nicotine-induced dopamine release in the nucleus accumbens (NAc), potentially reducing the addictive properties of nicotine while maintaining weight loss benefits.

GLP-1 drugs might reduce the 'high' or addictive feeling associated with nicotine, which could make it easier for smokers to quit or use nicotine-based therapies without the usual addiction risks.

Nutritional interventions, including supplements, do not provide additional benefit to mobility outcomes when combined with physical activity in older adults.

Do not rely on nutritional supplements to improve mobility. Focus on physical activity instead, as supplements have shown no additional benefit when combined with exercise for this population.

Brown adipose tissue (BAT) activation and the 'browning' of white adipose tissue (WAT) represent a potential therapeutic avenue for increasing energy expenditure and reducing body weight, although its clinical relevance in humans remains debated.

You can potentially increase your energy expenditure by activating brown fat, but this is not a guaranteed or standalone solution for weight loss. Strategies like cold exposure and sustained physical activity may promote 'browning' of white fat, turning it into heat-producing tissue. However, since its clinical impact is still debated, focus on these as complementary tools to a balanced diet and regular exercise, not replacements.

Inhibition of the p38 MAPK pathway in white adipose tissue promotes the reprogramming of white adipocytes to beige adipocytes, leading to resistance against diet-induced obesity.

Research suggests that targeting specific signaling pathways like p38 MAPK could potentially help convert energy-storing white fat into energy-burning beige fat, offering a potential future therapeutic strategy for obesity.

GLP-1 receptor agonists (semaglutide, tirzepatide) can cause excessive appetite suppression leading to restrictive eating behaviors, severe food aversion, dehydration, and acute kidney injury when used without intensive clinical monitoring.

If you are taking GLP-1 agonists (like Ozempic or Mounjaro), do not use them without regular medical supervision. Watch for signs of extreme food aversion, dehydration, or rapid weight loss. If you experience severe side effects like kidney issues or inability to eat, contact your doctor immediately. These drugs are powerful and require monitoring, especially if you have a history of eating disorders or have had bariatric surgery.

Environmental cold exposure and specific bioactive compounds (e.g., resveratrol, menthol) induce the browning of white adipose tissue (WAT) and activation of brown adipose tissue (BAT), thereby increasing energy expenditure and improving metabolic health.

You can potentially boost your metabolism by exposing yourself to cold or consuming specific compounds like resveratrol or menthol. These actions encourage your body to convert energy-storing white fat into energy-burning brown or beige fat. While cold exposure is effective, it may be uncomfortable, so exploring dietary sources of these compounds or exercise-induced browning might be more sustainable alternatives for long-term metabolic health.

Obesity and aging are associated with the 'whitening' of brown adipose tissue, characterized by lipid accumulation, loss of mitochondria, and impaired thermogenesis, which contributes to metabolic dysfunction.

As you age or gain weight, your body's ability to burn fat as heat (via brown fat) naturally declines, contributing to further weight gain and metabolic issues. This process is called 'whitening.' While you cannot reverse aging, you can potentially slow this decline by maintaining physical activity and exposing yourself to cold, which may help preserve your brown fat function and metabolic health.

Aging blunts the ability for serial sarcomerogenesis (addition of new sarcomeres in series), leading to shortened fascicle length and impaired muscle mechanical function, primarily due to age-related impairments in mechanotransduction pathways like mTOR, IGF-1, and SRF signaling.

For older adults, maintaining or improving muscle function may require specific interventions that promote muscle lengthening, such as eccentric resistance training or chronic stretching. While muscle mass loss is common, the shortening of muscle fascicles (due to loss of serial sarcomeres) contributes significantly to stiffness and reduced power. Targeted training that emphasizes the lengthening phase of movements may help mitigate these age-related architectural changes, though the response may be slower or smaller than in younger individuals.

Skeletal muscle releases myokines (such as Irisin and Myostatin) during exercise, which mediate interorgan crosstalk to improve metabolic health, regulate adipose tissue, and protect against cardiovascular disease.

Understand that exercise is a systemic therapy. When you move, your muscles release signals that improve the health of your heart, brain, and fat tissue, not just the muscles themselves.

Tirzepatide (TRZD) may increase the risk of cancer progression, specifically pancreatic and medullary thyroid cancer (MTC), through GLP-1R/GIPR-mediated activation of oncogenic pathways (PI3K/Akt/mTOR, Ras-Raf-ERK) and calcitonin release, particularly in patients with prior pancreatitis or family history of MTC.

If you have a personal or family history of Medullary Thyroid Cancer (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2), you should not use Tirzepatide. If you have a history of pancreatitis, use with caution and monitor for symptoms. For other diabetic patients, the long-term cancer risk is currently unknown, but the drug is approved for weight loss and glucose control. Discuss your specific cancer history with your provider before starting.

Tirzepatide (TRZD) and other GLP-1R/GIPR agonists may exhibit anti-cancer properties by sensitizing cancer cells to chemotherapy, inducing apoptosis, and inhibiting proliferation via pathways like PI3K/Akt/mTOR and AMPK, particularly in pancreatic, breast, and colorectal cancers.

Current research shows that drugs like Liraglutide and Exenatide can kill cancer cells or make chemo work better in lab mice. However, there is no proof yet that Tirzepatide does this in humans. Do not use these drugs as a cancer treatment outside of clinical trials.

High-dose omega-3 PUFA supplementation (1-4 g/d) increases the risk of new-onset atrial fibrillation, particularly in elderly patients or those with prior myocardial infarction, likely by prolonging action potential duration via Piezo1 channel modulation.

If you are taking high-dose omega-3 supplements (1-4 grams daily), especially if you are older or have had a heart attack, be aware that this may increase your risk of developing atrial fibrillation (an irregular heartbeat). Consult your doctor before maintaining high doses, as the benefits for inflammation may be offset by this specific cardiac risk.

Bariatric surgery (Roux-en-Y gastric bypass and sleeve gastrectomy) causes a significant decrease in fecal straight short-chain fatty acids (SCFAs), including acetate, propionate, butyrate, and valerate, likely due to altered dietary intake and microbiota fermentation.

If you have had bariatric surgery, expect your gut bacteria to produce fewer beneficial fatty acids (SCFAs) like butyrate. This is a normal physiological change due to the surgery and dietary shifts. To support your gut health, focus on the recommended post-surgical diet, which emphasizes protein and gradually reintroduces fiber-rich foods as tolerated, under the guidance of your healthcare team.

Peri-operative use of GLP-1 receptor agonists delays gastric emptying, increasing the risk of retained gastric contents and pulmonary aspiration during anesthesia, particularly in patients without diabetes or those recently initiating therapy.

If you take GLP-1 medications (like Ozempic or Wegovy) before surgery, tell your anesthesiologist immediately. These drugs slow stomach emptying, which can cause dangerous aspiration during anesthesia. You may need to fast longer or follow a clear-liquid diet for 24 hours before your procedure, even if it is elective. Do not assume standard fasting rules apply.

Whey protein supplementation without resistance training significantly reduces daily protein intake in postmenopausal women, suggesting a compensatory eating mechanism.

If you take whey protein but do not exercise, you might actually end up eating less protein from your regular meals. This means your total protein intake may drop, which is why you won't see muscle benefits. To increase protein, focus on whole foods or ensure the supplement doesn't replace other protein sources.

Stevia-derived Rebaudioside A improves liver steatosis, fibrosis, and glucose metabolism in NAFLD/NASH models by modulating gut microbiota and reducing oxidative stress.

For individuals with NAFLD or NASH, using Stevia (specifically Rebaudioside A) as a sweetener replacement for sugar may improve liver health, reducing fat accumulation and fibrosis, and improving glucose metabolism. This is achieved through positive changes in gut microbiota and reduced oxidative stress.

Moderate and frequent consumption of coffee is associated with a decreased risk of NAFLD and fibrosis, likely through the stimulation of hepatic stellate cell apoptosis and suppression of collagen synthesis.

Drinking at least one cup of coffee daily (moderate consumption) is associated with a lower risk of developing NAFLD and fibrosis. It may also improve liver function by lowering liver enzyme levels. This benefit is attributed to caffeine and chlorogenic acid.

Metabolic and bariatric surgery (MBS) often results in substantial weight regain in patients with monogenic or syndromic obesity, particularly those with MC4R pathway variants, making it less effective than targeted pharmacotherapy for these groups.

If you have a known genetic form of obesity, discuss the long-term risks of bariatric surgery with your doctor. Studies show that patients with MC4R pathway variants often regain significant weight after surgery because the underlying genetic hunger drive remains unaddressed.

Pharmacological inhibition of the postsynaptic scaffolding proteins PSD-95 (via UCCB01-147) and PICK1 (via mPD5) induces sustained weight loss in obese mice primarily through a non-aversive reduction in food intake, with effects persisting for days after treatment cessation.

This research identifies two specific brain proteins (PSD-95 and PICK1) that, when blocked by experimental drugs, cause obese mice to eat less without feeling sick, leading to significant fat loss that lasts for days after the drug is stopped. While not yet available for humans, this suggests a potential future treatment class that avoids the common side effects of current obesity drugs and offers sustained benefits.

Traditional Asian dietary practices, including the consumption of ulam, probiotics from fermented foods, and herbs like curcumin and green tea, reduce dementia risk through anti-inflammatory and gut-brain axis mechanisms.

Incorporate more fermented foods (yogurt, kimchi, miso), herbs like turmeric and green tea, and leafy vegetables into your diet. These support gut health and reduce inflammation, which benefits brain health.